Literature DB >> 28631017

Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Aline I Riechardt1, Bettina Karle2, Dino Cordini1,3, Jens Heufelder1,3, Volker Budach4, Antonia M Joussen1, Johannes Gollrad5,6.   

Abstract

PURPOSE: The aim of this study was to evaluate local tumour control, incidence of radiation-induced glaucoma and associated interventions of sector-based and whole anterior segment proton beam therapy (PBT) for the treatment of iris melanoma. PATIENTS AND METHODS: We retrospectively analysed the data of 77 patients with iris melanoma who underwent PBT applied as 50 CGE in four daily fractions. Of the patients, 47 received PBT with a circular-shaped collimator and 30 with a conformal sector-shaped target volume. Local control, eye preservation and secondary glaucoma were evaluated.
RESULTS: Median follow-up time was 54.9 months. Local tumour control was 100% in patients receiving whole anterior segment irradiation. Two patients developed pigment dispersion in the non-irradiated area after sector-based PBT and received whole anterior segment salvage PBT. The mean volume of ciliary body irradiated was 89.0% and 34.9% for whole anterior segment and lesion-based irradiation, respectively. At the end of follow-up, secondary glaucoma was found in 74.3% of the patients with whole anterior segment irradiation and in 19.2% with sector-based irradiation. Patients with sector-based PBT had a stable visual acuity of logMAR 0.1, while it declined from logMAR 0.1 to 0.4 after whole anterior segment irradiation.
CONCLUSION: We found a significant reduction in radiation-induced secondary glaucoma and glaucoma-associated surgical interventions and stable visual acuity after sector-based irradiation compared with whole anterior segment irradiation. Sector-based irradiation revealed a higher risk for local recurrence, but selected patients with well-circumscribed iris melanoma benefit from applying a lesion-based target volume when treated with sector-based PBT.

Entities:  

Keywords:  Iris neoplasms; Melanoma; Proton beam therapy; Targeted radiotherapy; Toxicity

Mesh:

Year:  2017        PMID: 28631017     DOI: 10.1007/s00066-017-1166-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  19 in total

1.  [Proton therapy of pediatric rhabdomyosarcoma: Same tumor control as photon therapy, with less adverse effects].

Authors:  Kristin Gurtner; Michael Baumann
Journal:  Strahlenther Onkol       Date:  2015-10       Impact factor: 3.621

2.  Proton beam radiotherapy of iris melanoma.

Authors:  Bertil Damato; Andrzej Kacperek; Mona Chopra; Martin A Sheen; Ian R Campbell; R Douglas Errington
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

3.  Proton beam therapy for iris melanoma: a review of 15 cases.

Authors:  P Rundle; A D Singh; I Rennie
Journal:  Eye (Lond)       Date:  2006-01-13       Impact factor: 3.775

4.  Iris melanoma: risk factors for metastasis in 169 consecutive patients.

Authors:  C L Shields; J A Shields; M Materin; E Gershenbaum; A D Singh; A Smith
Journal:  Ophthalmology       Date:  2001-01       Impact factor: 12.079

5.  Precise modelling of the eye for proton therapy of intra-ocular tumours.

Authors:  Barbara Dobler; Rolf Bendl
Journal:  Phys Med Biol       Date:  2002-02-21       Impact factor: 3.609

6.  Planning proton therapy of the eye.

Authors:  M Goitein; T Miller
Journal:  Med Phys       Date:  1983 May-Jun       Impact factor: 4.071

7.  Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey.

Authors:  Jan Hrbacek; Kavita K Mishra; Andrzej Kacperek; Remi Dendale; Catherine Nauraye; Michel Auger; Joel Herault; Inder K Daftari; Alexei V Trofimov; Helen A Shih; Yen-Lin E Chen; Andrea Denker; Jens Heufelder; Tomasz Horwacik; Jan Swakoń; Cornelia Hoehr; Cheryl Duzenli; Alessia Pica; Farid Goudjil; Alejandro Mazal; Juliette Thariat; Damien C Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-28       Impact factor: 7.038

8.  Plaque radiation therapy for malignant melanoma of the iris and ciliary body.

Authors:  P T Finger
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

9.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

10.  Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy.

Authors:  C L Shields; J A Shields; P De Potter; A D Singh; C Hernandez; L W Brady
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

View more
  3 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

2.  Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.

Authors:  Aline I Riechardt; Julian P Klein; Dino Cordini; Jens Heufelder; Matus Rehak; Ira Seibel; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-20       Impact factor: 3.117

3.  Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma.

Authors:  Valerie Schmelter; Sarah Heidorn; Alexander Muacevic; Siegfried G Priglinger; Paul Foerster; Raffael Liegl
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.